Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use YIMMUGO safely and effectively. See full prescribing information for YIMMUGO. YIMMUGO (immune globulin intravenous, human - dira), 10% liquid Initial U.S. Approval: 2024
Medication labelWhy this: Advisory · dailymed-other
YIMMUGO (immune globulin intravenous, human – dira), is a 10% immune globulin liquid, indicated for the treatment of primary humoral immunodeficiency (PI) including but not limited to the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia (XLA), Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID) in patients 2 years of age and older.
- generic_name
- immune globulin intravenous, human - dira
- product_names
- immune globulin intravenous, human - dira
- ndc
- 70573-605, 70573-605-02, 70573-605-01, 70573-605-12, 70573-605-11, 70573-605-22, 70573-605-21
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en